Article Details

GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB ...

Retrieved on: 2022-04-11 18:59:34

Tags for this article:

Click the tags to see associated articles and topics

GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB .... View article details on hiswai:

Excerpt

GTB-5550 is the Company's B7H3-targeted tri-specific killer engager (TriKE) and is part of GT Biopharma's portfolio of TriKE product candidates being ...

Article found on: pipelinereview.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up